BBLG net incomeQ3 2026-$617.7K
BBLG net income was -$617.7K in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$666.7K a year earlier. For the full fiscal 2025 it was -$3.11M, compared with -$4.11M in fiscal 2024.
Bone Biologics Corp (BBLG) financials
For the twelve months ended Sep 30, 2026, Bone Biologics Corp reported -$2.84M of net income.
- Net income, TTM
- -$2.84M
- Cash
- $6.09M
- Market cap
- $1.1M
FY2016FY2020
FY2016FY2025
BBLG revenue and earnings growth
BBLG EPSQ3 2026-$0.17
BBLG diluted EPS was -$0.17 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$2.65.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $1.07B | $1.07B | - | - | $1.07B |
| Research and development | $1.06M | $2.13M | $6.91M | $1.58M | $82.0K | $340.7K | $1.10M | $104.5K | $1.42M | $10.17M |
| Selling, general and admin | $2.17M | $2.09M | $2.52M | $2.09M | $1.02M | $484.3K | $1.35M | $2.69M | $3.96M | $5.65M |
| Operating income | -$3.23M | -$4.22M | -$9.43M | -$3.67M | -$1.10M | -$825.0K | -$2.45M | -$2.79M | -$2.63M | -$20.41M |
| Pre-tax income | - | - | - | - | -$1.61M | -$1.82M | -$3.42M | -$4.43M | -$7.05M | -$25.88M |
| Income tax | - | - | - | - | $1.6K | $1.6K | $1.6K | $1.7K | $1.6K | $2.2K |
| Net income | -$3.11M | -$4.11M | -$8.95M | -$1.48M | -$1.61M | -$1.82M | -$3.42M | -$4.43M | -$7.05M | -$25.88M |
| EPS, basic | -$2.65 | -$28.96 | -$34.01 | -$31.15 | -$0.35 | -$0.63 | -$1.17 | -$2.20 | -$4.52 | -$17.25 |
| EPS, diluted | -$2.65 | -$28.96 | -$34.01 | -$31.15 | -$0.35 | -$0.63 | -$1.17 | -$2.20 | -$4.52 | -$17.25 |
| Diluted shares | 1.2M | 252,960 | 263,137 | 47,658 | 4.5M | 2.9M | 2.9M | 2.0M | 1.6M | 1.5M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.33M | $3.33M | $3.03M | $7.54M | $6.68M | - | $24.1K | $955.4K | $690.3K | $620.4K |
| Current assets | $5.80M | $3.86M | $3.74M | $8.50M | - | - | $30.8K | $1.04M | $795.5K | $700.9K |
| Total assets | $5.80M | $3.86M | $3.74M | $8.50M | $6.68M | $0 | $30.8K | $1.04M | $795.7K | $701.1K |
| Current liabilities | $418.6K | $377.7K | $831.4K | $2.55M | $99.9K | $13.69M | $578.4K | $9.64M | $961.8K | $1.50M |
| Total debt | - | - | - | - | - | - | - | - | - | $7.56M |
| Total liabilities | $418.6K | $377.7K | $831.4K | $2.55M | $99.9K | $13.69M | $11.90M | $9.64M | $9.19M | $9.06M |
| Shareholders' equity | $5.38M | $3.48M | $2.91M | $5.95M | $6.58M | -$13.69M | -$11.87M | -$8.60M | -$8.40M | -$8.36M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.69M | -$4.12M | -$9.56M | -$3.57M | -$1.23M | -$426.9K | -$3.25M | -$4.10M | -$3.33M | -$7.33M |
| Financing cash flow | $4.70M | $4.42M | $5.04M | $4.43M | $7.90M | $402.8K | $2.32M | $4.37M | $3.40M | $6.83M |
| Stock-based compensation | $256.4K | $188.8K | $152.6K | $266.6K | $207.0K | - | $49.7K | $516.6K | $1.62M | $4.14M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | 0.0% | - | - | - | - |
| Operating margin | - | - | - | - | - | -0.1% | -0.2% | - | - | -1.9% |
| Net margin | - | - | - | - | - | -0.2% | -0.3% | - | - | -2.4% |
| Return on equity | -57.8% | -118.0% | -307.9% | -25.0% | -24.5% | - | - | - | - | - |
| Return on assets | -53.6% | -106.5% | -239.4% | -17.5% | -24.1% | - | -11109.8% | -425.7% | -886.3% | -3690.9% |
| Current ratio | 13.85 | 10.22 | 4.50 | 3.33 | - | - | 0.05 | 0.11 | 0.83 | 0.47 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $242.6K | $308.7K | $141.6K | $257.2K | $187.8K | $191.6K | $423.6K | $1.10M | $429.7K | $350.4K | $245.6K | $447.1K |
| Selling, general and admin | $423.8K | $499.4K | $663.5K | $475.9K | $527.5K | $556.5K | $614.9K | $450.4K | $521.3K | $459.2K | $657.9K | $712.9K |
| Operating income | -$666.3K | -$808.1K | -$805.1K | -$733.1K | -$715.3K | -$748.1K | -$1.04M | -$1.55M | -$951.0K | -$809.7K | -$903.5K | -$1.16M |
| Net income | -$617.7K | -$773.7K | -$766.0K | -$684.6K | -$666.7K | -$740.5K | -$1.02M | -$1.52M | -$941.0K | -$783.7K | -$866.0K | -$1.55M |
| EPS, basic | -$0.17 | -$0.43 | -$0.43 | - | -$0.37 | -$1.33 | -$1.92 | - | -$14.21 | -$4.02 | -$1.31 | - |
| EPS, diluted | -$0.17 | -$0.43 | -$0.43 | - | -$0.37 | -$1.33 | -$1.92 | - | -$14.21 | -$4.02 | -$1.31 | - |
| Diluted shares | 3.7M | 1.8M | 1.8M | - | 1.8M | 557,787 | 530,618 | - | 292,321 | 194,824 | 660,928 | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.09M | $4.03M | $4.53M | $5.33M | $6.05M | $6.64M | $2.75M | $3.33M | $3.57M | $2.33M | $3.23M | $3.03M |
| Current assets | $6.43M | $4.44M | $4.98M | $5.80M | $6.35M | $7.00M | $3.16M | $3.86M | $4.07M | $3.19M | $3.84M | $3.74M |
| Total assets | $6.43M | $4.44M | $4.98M | $5.80M | $6.35M | $7.00M | $3.16M | $3.86M | $4.07M | $3.19M | $3.84M | $3.74M |
| Current liabilities | $480.8K | $512.0K | $309.4K | $418.6K | $334.3K | $406.1K | $251.2K | $377.7K | $273.4K | $284.5K | $164.6K | $831.4K |
| Total liabilities | $480.8K | $512.0K | $309.4K | $418.6K | $334.3K | $406.1K | $251.2K | $377.7K | $273.4K | $284.5K | $164.6K | $831.4K |
| Shareholders' equity | $5.95M | $3.92M | $4.67M | $5.38M | $6.02M | $6.60M | $2.91M | $3.48M | $3.79M | $2.91M | $3.67M | $2.91M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$532.3K | -$518.4K | -$804.3K | -$714.8K | -$591.4K | -$458.9K | -$926.1K | -$1.35M | -$572.2K | -$895.9K | -$1.30M | -$2.02M |
| Financing cash flow | $2.59M | - | - | $0 | $0 | $4.35M | $347.5K | $1.11M | $1.81M | $299 | $1.50M | $592.0K |
| Stock-based compensation | $3.4K | $8.3K | $23.5K | $45.7K | $87.2K | $72.9K | $50.6K | $100.8K | $17.9K | $17.4K | $52.7K | $71.1K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 13.38 | 8.67 | 16.09 | 13.85 | 19.00 | 17.24 | 12.59 | 10.22 | 14.87 | 11.22 | 23.32 | 4.50 |
Source: XBRL data Bone Biologics Corp files with the SEC, latest filing dated Oct 26, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Aug 14, 2018; 2-for-5, first reported Nov 15, 2021.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
BBLG peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BBLG | - | - | -$2.84M | - | $1.1M |
| ISRG | $11.58B | +20.5% | $2.96B | 25.5% | $159.65B |
| EW | $6.67B | +13.4% | $1.02B | 15.3% | $60.21B |
| STE | $6.17B | +8.1% | $826.90M | 13.4% | $24.95B |
| ZBH | $8.57B | +7.0% | $767.30M | 9.0% | $20.50B |
| MAS | $7.67B | +0.9% | $926.00M | 12.1% | $16.56B |
| SNN | $6.16B | +6.1% | $625.00M | 10.1% | $13.00B |
| ALGN | $4.16B | +4.4% | $491.87M | 11.8% | $12.28B |
| AIT | $5.06B | +8.5% | $424.12M | 8.4% | $10.86B |
BBLG FAQ
4 questionsIs BBLG profitable?
No. Bone Biologics Corp reported a net loss of $2.84M for the twelve months ended Sep 30, 2026.How much cash and debt does BBLG have?
Bone Biologics Corp reported $6.09M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did BBLG last report financial results?
The latest statements here come from Bone Biologics Corp's 10-Q filed on Oct 26, 2026, covering the period ended Sep 30, 2026.Where does this BBLG financial data come from?
Quantisnow builds these statements from the structured XBRL data Bone Biologics Corp files with the SEC. It is provided for information only and is not investment advice.